Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113361 (NCT01313637)
- Testing
- GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 1,493 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
- Trial name
- NCT00949975
- Testing
- AZD9668
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 838 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
The purpose of this study is to monitor the change in the health status of severe COPD patients after the initiation of Tiotropium therapy.
- Trial name
- NCT00624377
- Testing
- Tiotropium
- Where
- 17 sites in Taiwan
- Volunteers
- 2,031 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
The primary objective of this observational study is to determine the incidence of medically attended (inpatient or outpatient) acute respiratory illnesses or events leading to worsening cardiorespiratory status (ie, acute…
- Trial name
- CD-1089 (NCT01455402)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 476 people
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need…
- Trial name
- NCT02719639
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 7,443 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Single Ascending Dose Study of TRN-157 in Healthy Subjects
This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.
- Trial name
- NCT02133339
- Testing
- TRN-157
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Theron Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.
The aim of the ORESTES study is to describe the characteristics of the COPD patients initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their real-world outcomes up to 12 months afterwards.
- Trial name
- ORESTES (NCT06321731)
- Where
- 15 sites in Spain
- Volunteers
- 718 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-centre, randomised, double-blind, double-dummy, two way cross-over, 12 weeks noninferiority study to evaluate the efficacy, safety, and tolerability of FSC 250/50 mcg capsule-based inhaler and a multi-dose inhaler…
- Trial name
- NCT01978145
- Testing
- FSC
- Where
- 52 sites in Argentina, Mexico and 2 more
- Volunteers
- 665 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD
- Trial name
- NCT00581945
- Testing
- Canakinumab
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis
COPD
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.
- Trial name
- NCT00691405
- Testing
- Arformoterol tartrate inhalation solution
- Where
- 31 sites in United States
- Volunteers
- 215 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233894
- Testing
- Atrovent® - inhalets
- Volunteers
- 526 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of…
- Trial name
- NCT00106821
- Testing
- Tiotropium Bromide Inhalation Powder
- Where
- 19 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to assess the equivalence of closed triple therapy Fluticasone Furoate (FF)/Umeclidinium (UMEC)/Vilanterol (VI) to open triple therapy (FF/VI + UMEC), with a comparison of both triple…
- Trial name
- NCT02731846
- Testing
- Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg
- Where
- 11 sites in Canada, Germany
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01053988
- Testing
- FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder
- Where
- 132 sites in United States, Chile and 8 more
- Volunteers
- 1,031 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic…
- Trial name
- NCT03414541
- Testing
- DS102
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Afimmune
Pulmonary Disease, Chronic Obstructive
ScreenFlow: Strategy for Finding Cases of Moderate-to-Severe COPD
ScreenFlow is a chronic obstructive pulmonary disease (COPD) screening tool currently being studied and iteratively developed that incorporates a questionnaire administered on a tablet and data from a digital peak flow meter to…
- Trial name
- NCT02753556
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
- Trial name
- SHINE (NCT01202188)
- Testing
- indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149)
- Where
- 166 sites in United States, Australia and 17 more
- Volunteers
- 2,144 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease
Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI)…
- Trial name
- NCT02968914
- Testing
- Benralizumab
- Where
- 2 sites in Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.